[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600005":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":99,"centralContacts":104,"locations":110,"responsibleParty":162,"collaborators":90,"id":164,"slug":165,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":90,"eligibilityCriteria":170,"healthyVolunteers":166,"sex":171,"minAge":172,"maxAge":90,"enrollmentInfo":173,"targetDuration":90,"studyType":176,"phases":177,"briefSummary":179,"conditions":180,"keywords":90,"overallStatus":150,"whyStopped":90,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A (SOC, CGM)","EXPERIMENTAL","Patients receive SOC treatment plus CGM with endocrinology-guided interventions as needed and attend dietary counseling sessions once a month for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the trial.",[13,14,15,16,17,18,19],"Other: Best Practice","Procedure: Biospecimen Collection","Other: Dietary Intervention","Procedure: Magnetic Resonance Imaging","Other: Monitoring","Other: Questionnaire Administration","Other: Supportive Care",{"label":21,"type":22,"description":23,"interventionNames":24},"Arm B (SOC, intermittent glucose monitoring)","ACTIVE_COMPARATOR","Patients receive SOC treatment plus intermittent glucose monitoring as clinically indicated for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the trial.",[13,14,25,16,18],"Other: Glucose Measurement",[27,34,43,53,60,80,86,91],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Best Practice","Receive SOC treatment",[9,21],[32,33],"standard of care","standard therapy",{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"PROCEDURE","Biospecimen Collection","Undergo blood sample collection",[9,21],[40,41,42],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Dietary Intervention","Attend dietary counseling sessions",[9],[48,49,50,51,52],"Dietary Modification","intervention, dietary","Nutrition Intervention","Nutrition Interventions","Nutritional Interventions",{"type":6,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"Glucose Measurement","Undergo intermittent glucose monitoring",[21],[58,59],"GLUC","Glucose",{"type":35,"name":61,"description":62,"armGroupLabels":63,"otherNames":64},"Magnetic Resonance Imaging","Undergo MRI",[9,21],[65,66,67,68,69,70,71,72,73,74,75,76,77,78,79],"Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI",{"type":6,"name":81,"description":82,"armGroupLabels":83,"otherNames":84},"Monitoring","Undergo CGM",[9],[85],"monitor",{"type":6,"name":87,"description":88,"armGroupLabels":89,"otherNames":90},"Questionnaire Administration","Ancillary studies",[9,21],null,{"type":6,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"Supportive Care","Receive endocrinology-guided interventions",[9],[96,97,98],"Supportive Therapy","Symptom Management","Therapy, Supportive",[100],{"name":101,"affiliation":102,"role":103},"Gelareh Zadeh, MD, PhD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[105],{"name":106,"role":107,"phone":108,"phoneExt":90,"email":109},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[111,132,149],{"facility":112,"status":113,"city":114,"state":115,"zip":116,"country":117,"countryCode":118,"cosmosGeoPoint":119,"geoPoint":124,"contacts":125},"Mayo Clinic in Arizona","NOT_YET_RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":120,"coordinates":121},"Point",[122,123],-112.07404,33.44838,{"lat":123,"lon":122},[126,127,130],{"name":106,"role":107,"phone":108,"phoneExt":90,"email":109},{"name":128,"role":107,"phone":129,"phoneExt":90,"email":90},"Yazmeen Nims","480-342-2906",{"name":131,"role":103,"phone":90,"phoneExt":90,"email":90},"Bernard Bendok, MD",{"facility":133,"status":113,"city":134,"state":135,"zip":136,"country":117,"countryCode":118,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Mayo Clinic in Florida","Jacksonville","Florida","32224",{"type":120,"coordinates":138},[139,140],-81.65565,30.33218,{"lat":140,"lon":139},[143,144,147],{"name":106,"role":107,"phone":108,"phoneExt":90,"email":109},{"name":145,"role":107,"phone":146,"phoneExt":90,"email":90},"General Clinical Studies Unit","904-953-2255",{"name":148,"role":103,"phone":90,"phoneExt":90,"email":90},"Alfredo Quinones-Hinojisa, MD",{"facility":102,"status":150,"city":151,"state":152,"zip":153,"country":117,"countryCode":118,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"RECRUITING","Rochester","Minnesota","55905",{"type":120,"coordinates":155},[156,157],-92.4699,44.02163,{"lat":157,"lon":156},[160,161],{"name":106,"role":107,"phone":108,"phoneExt":90,"email":109},{"name":101,"role":103,"phone":90,"phoneExt":90,"email":90},{"type":163,"investigatorFullName":90,"investigatorTitle":90,"investigatorAffiliation":90,"oldNameTitle":90,"oldOrganization":90},"SPONSOR","100600005","continuous-glucose-monitoring-for-the-management-of-hyperglycemia-in-patients-with-glioblastoma-100600005",false,"NCT07091864","Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma","Phase II Randomized Trial Of Glucose Monitoring In Glioblastoma","Inclusion Criteria:\n\n* Presumed newly diagnosed GBM based on imaging findings consistent with GBM on brain MRI (e.g., heterogeneously enhancing mass with central necrosis and surrounding edema), as determined by the treating neuro-oncology team\n* Age ≥ 18 years at the time of consent\n* Negative serum pregnancy test within 7 days prior to registration for individuals of childbearing potential\n* Karnofsky performance status (KPS) ≥ 70 at baseline\n* Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL (performed within 14 days prior to registration)\n* Platelet count ≥ 100 × 10\\^9\u002FL (performed within 14 days prior to registration)\n* Hemoglobin ≥ 9 g\u002FdL (performed within 14 days prior to registration)\n* Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL\u002Fmin (performed within 14 days prior to registration)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (performed within 14 days prior to registration)\n* Total bilirubin ≤ 1.5 × ULN (performed within 14 days prior to registration)\n* Willingness and ability to comply with CGM device use and attend dietary counseling sessions as per standard of care\n\nExclusion Criteria:\n\n* Recurrent glioblastoma\n* History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months\n* Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the opinion of the investigator, would interfere with study participation or interpretation of results\n* Concurrent diagnosis of another active malignancy requiring treatment\n* Pregnancy or breastfeeding at the time of registration\n* Documented history of type 1 diabetes mellitus","ALL","18 Years",{"count":174,"type":175},116,"ESTIMATED","INTERVENTIONAL",[178],"NA","This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy. Studies have shown that having a higher-than-normal amount of glucose in the blood (hyperglycemia) during radiation therapy is associated with poorer survival outcomes in glioblastoma patients. Hyperglycemia in glioblastoma patients is often driven by steroids that are commonly used during treatment. CGM uses a device that places a sensor under the skin that monitors glucose levels at regular intervals, providing real-time, or near real-time, glucose information. This can help to identify when a patient has changes in their glucose levels so they may receive necessary interventions or medications sooner. CGM may be an effective way for glioblastoma patients to manage their glucose levels, which may improve survival.",[181,182],"Glioblastoma, IDH-Wildtype","WHO Grade 4 Glioma","2026-08-13",{"date":185,"type":186},"2026-08-17","ACTUAL",{"date":188,"type":186},"2025-07-29",{"date":190,"type":175},"2027-11-30",{"name":5,"class":6},3]